Alzheimer's drug company Chase Pharmaceuticals has added $12m to its funding total, which is likely to have included $3m from existing investor Cipla.
US-based Alzheimer’s disease treatment developer Chase Pharmaceuticals has raised $12m in equity funding according to a securities filing, with the round likely to have included drug manufacturer Cipla.
India-based Cipla invested $3m in Chase, the Economic Times reported two weeks ago citing a Bombay Stock Exchange filing, shortly after Chase secured $3.5m in funding, as indicated by another securities filing.
Chase is working on treatments for neurodegenerative disorders, and in particular Alzheimer’s disease.
The company’s lead drug program, CPC-201,…
